BRAF and metastatic melanoma: In this paper, we report a case of a patient with BRAF-mutated metastatic melanoma harbouring many genetic mutations who did not respond to targeted therapies (BRAF and MEK inhibitors) or to immune checkpoint inhibitors, such as ipilimumab and nivolumab, but presented an impressive and dramatic response to subsequent cytotoxic chemotherapy consisting of dacarbazine and cisplatin.